Merck & Co.
Develops intismeran autogene, a personalized mRNA cancer vaccine, with Moderna.
The ASCO Post, 21 Aug 2026Prices by TradingView, about 15 minutes delayed. Not investment advice.
- Ticker
- MRK · NYSE
- Based in
- United States
- Website
- merck.com ↗
How nano is it?
No filing of theirs says yet
We flag how much of a business is nanotechnology only when the company's own filings say it. Until then we describe what it makes.
What we track
Its technologies, and how far each has got
On the record
Latest steps
The newest dated events on the technologies above.
- Human trial
mRNA cancer vaccine
Full results from 1,137 patients, presented at the ESMO Congress in Madrid: adding the vaccine to Keytruda cut the risk of recurrence or death by 42%.
“I’m genuinely excited about the results, and it is important to understand this is more than just a new drug.”Patrick Ott, Clinical director of the Melanoma Disease Center, Dana-Farber Cancer Institute
Healio, 23 Oct 2026 - Human trialCompany-reported
mRNA cancer vaccine
Merck and Moderna said their phase 3 trial in people whose high-risk melanoma had been removed met its main goal: with Keytruda, the vaccine lowered the risk of the cancer returning.
The ASCO Post, 21 Aug 2026
Not investment advice. We describe what companies do and what their own filings say; we never say whether to buy or sell.